Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | USP9X | Q93008 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382273 | 0.98 | EPHX2 (0.38) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL3434555 | 0.98 | EPHX2 (0.38) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL13890730 | 0.95 | — | — | |
| SCHEMBL57030 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL28314935 | 0.88 | — | — | |
| Ether SCHEMBL2398678 | 0.84 | ELOVL1 (0.33) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL14704914 | 0.82 | MEN1 (0.38) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL15191961 | 0.82 | HTT (0.37) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL1455913 | 0.82 | EPHX2 (0.37) | EPHX2ELOVL1HCAR2CYP2D6HRH1 | |
| SCHEMBL30206149 | 0.81 | EPHX2 (0.37) | EPHX2ELOVL1HCAR2CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293381-A1 | Therapeutic Compounds | CELGENE QUANTICEL RES INC (US) | 2024-09-05 | — | — | US | claimed |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-07-08 | — | — | US | claimed |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-28 | — | — | US | claimed |
| US-10617680-B2 | Therapeutic compounds | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-14 | — | — | US | claimed |
| EP-3612522-A1 | THERAPEUTIC COMPOUNDS | Celgene Quanticel Research, Inc. (US) | 2020-02-26 | — | — | EP | claimed |
| WO-2018195155-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-25 | — | — | WO | claimed |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | CELGENE QUANTICEL RESEARCH, INC. | 2018-10-18 | — | — | US | claimed |
| EP-4646410-A1 | TUBULIN POLYMERIZATION INHIBITORS | AB Science (FR) | 2025-11-12 | — | — | EP | disclosed |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | REDX PHARMA PLC (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | GENENTECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | GENENTECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| CN-113330000-B | 3-Carbonylamino-5-cyclopentyl-1 FI-pyrrole compounds having inhibitory activity on CDK2 | 辉瑞公司 | 2024-12-24 | — | — | CN | disclosed |
| US-20240293381-A1 | Therapeutic Compounds | CELGENE QUANTICEL RES INC (US) | 2024-09-05 | — | — | US | disclosed |
| EP-2063897-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008131227-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008034008-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007002258-A2 | BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| CN-1835953-A | 4-Cycloalkylaminopyrazolopyrimidine NMDA/NR2B antagonists | MERCK & CO INC (US) | 2006-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | CDK2, CCNI, CDK20 | EPHX2 2570/4885ELOVL1 3589/4885HCAR2 4665/4885 |
| US-12202826-B2 | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway | WNT1, WNT3, CTNNB1 | EPHX2 4558/4885ELOVL1 3091/4885HCAR2 1568/4885 |
| US-20240293381-A1 | Therapeutic Compounds | EP300, BRD4, BRD3 | EPHX2 3597/4885ELOVL1 1266/4885HCAR2 2349/4885 |
| US-20200163946-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | EPHX2 3597/4885ELOVL1 1266/4885HCAR2 2349/4885 |
| US-20180296543-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | EPHX2 3597/4885ELOVL1 1266/4885HCAR2 2349/4885 |
| US-20210205284-A1 | THERAPEUTIC COMPOUNDS | EP300, BRD4, BRD3 | EPHX2 3597/4885ELOVL1 1266/4885HCAR2 2349/4885 |
| US-10617680-B2 | Therapeutic compounds | EP300, BRD4, BRD3 | EPHX2 3597/4885ELOVL1 1266/4885HCAR2 2349/4885 |
| US-20080261965-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES | KIT, PRKACA, BRAF | EPHX2 2351/4885ELOVL1 3747/4885HCAR2 2611/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | EPHX2 3487/4885ELOVL1 3358/4885HCAR2 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.